{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 64,
  "pageCount": 95,
  "prevPage": 63,
  "nextPage": 65,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/64",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-64",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.142,
        "y": 0.75
      },
      "kind": "list",
      "text": "Fast track approval of NDA. Reduced FDA fees and costs. One Phase III instead of two.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c563b4f3-4fb0-4c09-9bbe-d42096c52f2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.6,
        "x": 0.142,
        "y": 0.248
      },
      "kind": "paragraph",
      "text": "The FDA has an accelerated approval program to allow NDA approval for patients with unmet medical needs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41c6dc08-4d0a-4f98-978f-046a3a2b3cfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.6,
        "x": 0.142,
        "y": 0.578
      },
      "kind": "paragraph",
      "text": "We will be exploring a path for accelerated approval which would reduce the time and costs of the MM-120 development:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9821c961-89dc-4856-aa8f-5a054dc085ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.6,
        "x": 0.142,
        "y": 0.407
      },
      "kind": "paragraph",
      "text": "Although there are drugs approved or in development for general anxiety disorder, there are patients that fit into an unmet medical need.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a41e6fca-2e4a-4452-95ea-a4fdc09a17a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.046,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: FDA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "608e038e-a5d5-475d-a60b-654c568a083b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.046,
        "y": 0.056
      },
      "kind": "title",
      "text": "FDA Accelerated Approval",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "697a1833-5c72-4030-a464-5f5dde653702",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 95,
      "from": 61,
      "beatId": "383f2f65-7b68-449f-b311-9bc0591c8aab",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Freeman Capital Management's plan to restore value in Mind Medicine, including bringing MM-120 to market quickly and safely, and aligning G&A and headcount.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 70,
      "from": 62,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "86491bd2-85cc-4539-897c-03a8ac16c31c",
      "evidence": "The document presents Freeman Capital Management's plan to bring MM-120 to market quickly and safely, and to align G&A and headcount.",
      "position": 1,
      "objective": "What are the quick wins and big bets that Freeman Capital Management can make to restore value in Mind Medicine?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}